Chasing rivals, AbbVie files migraine prevention drug atogepant in EU
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their recently-approved Vydura drug. The EMA filing for atogepant covers the prevention of migraine in adults who have at least four migraine days per month …
Chasing rivals, AbbVie files migraine prevention drug atogepant in EU Read More »